NCT05120297 - A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis | Biotech Hunter

Enrollment

452

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

September 29, 2022

Study Completion Date

September 29, 2022

Conditions

Psoriasis Vulgaris

Interventions

DRUG

AK101

Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.

DRUG

Placebo

Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.

Trial Locations (52)

Unknown

AkesoBio Investigative Site 1010, Bengbu

AkesoBio Investigative Site 1028, Hefei

AkesoBio Investigative Site 1013, Wuhu

AkesoBio Investigative Site 1001, Beijing

AkesoBio Investigative Site 1027, Beijing

AkesoBio Investigative Site 1034, Beijing

AkesoBio Investigative Site 1035, Beijing

AkesoBio Investigative Site 1036, Beijing

AkesoBio Investigative Site 1049, Beijing

AkesoBio Investigative Site 1051, Beijing

AkesoBio Investigative Site 1041, Chongqing

AkesoBio Investigative Site 1007, Guangzhou

AkesoBio Investigative Site 1021, Guangzhou

AkesoBio Investigative Site 1024, Guangzhou

AkesoBio Investigative Site 1018, Shenzhen

AkesoBio Investigative Site 1023, Shenzhen

AkesoBio Investigative Site 1030, Shenzhen

AkesoBio Investigative Site 1012, Nanning

AkesoBio Investigative Site 1039, Guiyang

AkesoBio Investigative Site 1025, Chengde

AkesoBio Investigative Site 1017, Shijiazhuang

AkesoBio Investigative Site 1031, Shijiazhuang

AkesoBio Investigative Site 1014, Harbin

AkesoBio Investigative Site 1033, Nanyang

AkesoBio Investigative Site 1045, Zhengzhou

AkesoBio Investigative Site 1004, Wuhan

AkesoBio Investigative Site 1006, Changsha

AkesoBio Investigative Site 1026, Changsha

AkesoBio Investigative Site 1052, Lianyungang

AkesoBio Investigative Site 1029, Nanjing

AkesoBio Investigative Site 1009, Xuzhou

AkesoBio Investigative Site 1015, Yancheng

AkesoBio Investigative Site 1019, Nanchang

AkesoBio Investigative Site 1020, Nanchang

AkesoBio Investigative Site 1032, Changchun

AkesoBio Investigative Site 1047, Changchun

AkesoBio Investigative Site 1008, Dalian

AkesoBio Investigative Site 1048, Shenyang

AkesoBio Investigative Site 1050, Hohhot

AkesoBio Investigative Site 1044, Yinchuan

AkesoBio Investigative Site 1038, Jinan

AkesoBio Investigative Site 1042, Jinan

AkesoBio Investigative Site 1043, Qingdao

AkesoBio Investigative Site 1005, Shanghai

AkesoBio Investigative Site 1046, Taiyuan

AkesoBio Investigative Site 1011, Chengdu

AkesoBio Investigative Site 1016, Suining

AkesoBio Investigative Site 1040, Tianjin

AkesoBio Investigative Site 1037, Kunming

AkesoBio Investigative Site 1002, Hangzhou

AkesoBio Investigative Site 1003, Hangzhou

AkesoBio Investigative Site 1022, Hangzhou